ما هو علاج ورم الظهارة المتوسطة الجنبي المشخص حديثاً ذي الأنسجة الظهارية؟

References

DOI: 10.1200/JCO-24-02425

• In patients with newly diagnosed epithelioid mesothelioma, ipilimumab plus nivolumab immunotherapy should be offered as a first-line systemic treatment option.
• In patients with epithelioid histology, pemetrexed plus platinum-based chemotherapy with or without bevacizumab may be offered as a first-line systemic treatment option.
• In patients who have received both immunotherapy and pemetrexed plus platinum-based chemotherapy, vinorelbine or gemcitabine ± ramucirumab may be offered.
• Retreatment with pemetrexed-based chemotherapy may be offered to patients with pleural mesothelioma who achieved durable (>6 months) disease control with first-line pemetrexed-based chemotherapy.